Literature DB >> 33740477

Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.

Jeffrey V Lazarus1, Camila A Picchio2, Danielle Guy2, Soo Aleman3, Cary James4, Felice A Nava5, Anne Øvrehus6, Juan Turnes7, John W Ward8, Andy Ustianowski9.   

Abstract

Significant steps must be taken to reduce the global incidence and prevalence of hepatitis C virus (HCV) and mortality from HCV infection to achieve the WHO goal of eliminating viral hepatitis as a public health threat by 2030. Proper epidemiological surveillance of the full continuum of care is essential for monitoring progress and identifying gaps that need to be addressed. The tools required for elimination have largely been established, and the issue at hand is more how they should best be implemented in different settings around the world. Documenting good practices allows for knowledge exchange to prevent transmission and improve health outcomes for people with HCV. This review found 13 well documented HCV good practices that have become the standard of care or that should become the standard of care as soon as possible. In 2013, highly effective direct-acting antiviral therapy became available, which has cure rates of over 95%. Together with this new therapy, evidence-based good practices can help countries eliminate viral hepatitis C.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Disease elimination; Good practices in healthcare; Health policy; Review; Viral hepatitis C

Mesh:

Substances:

Year:  2021        PMID: 33740477     DOI: 10.1016/j.clinre.2020.11.001

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

1.  Entry Inhibitors of Hepatitis C Virus.

Authors:  Xi-Jing Qian; Zhong-Tian Qi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.

Authors:  Maria Buti; Jeffrey V Lazarus; Camila A Picchio; Sabela Lens; Manuel Hernandez-Guerra; Juan Arenas; Raúl J Andrade; Javier Crespo; Javier García-Samaniego; Manuel Romero-Gómez; Juan Turnes; José Luis Calleja; Miguel Ángel Simón; Trenton M White; Mar Riveiro-Barciela; Anna Pocurull; Dalia Morales-Arraez; Alexandra Gómez
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.996

3.  Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific miR-4423-3p Targets RIG-I to Facilitate Infection.

Authors:  Xijing Qian; Bingan Wu; Chen Xu; Zhongtian Qi
Journal:  Front Cell Infect Microbiol       Date:  2022-03-24       Impact factor: 5.293

4.  Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.

Authors:  Lewis Beer; Sarah Inglis; Amy Malaguti; Christopher Byrne; Christian Sharkey; Emma Robinson; Kirsty Gillings; Andrew Radley; Adrian Hapca; Brian Stephens; John Dillon
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.